Patent ID: 12233281

DETAILED DESCRIPTION OF AN EXAMPLE OF A PREFERRED EMBODIMENT

With reference to the figures, the device of the invention consists of two laminar layers of transparent plastic, the transparent insulating plastic laminar element1and the insulating transparent plastic laminar element4, preferably flexible, a first one with a supporting function and a second one with protective and insulating function, which enclose and confine a mixture of quantum dots2.

Generally, this mixture also includes a percentage of carbon nanotubes, in order to arrive at the precise percentage of this mixture of quantum dots2, and also due to their conductive effect, which allows the radiation to be received that stimulate the quantum dots and therefore the photonic emissions of said mixture to be transmitted outside the device.

To facilitate the printing on a wall between the two outer layers of the mixture of quantum dots, the mixture is dispersed in a transparent ink.

To ensure the flexibility of the device and to prevent the two outer layers1,4separating, a double-sided adhesive3is used, preferably suitable for coming into contact with a person's skin, which retains two layers1,4that are joined together, including the mixture of quantum dots2.

To render said device even more flexible, the outer layers are limited to a thickness of a few tenths of a millimetre to a few millimetres, preventing breakage or cracking following significant bending.

This flexible double-sided adhesive3also makes it more reliable over time, having a modulus of elasticity greater than the layers, but the adhesive allowing possible sliding between the layers of the composite device.

The wall of the support1that will come into contact with the patient's skin is applied, either directly or with the interposition of a removable plaster, onto the skin to be treated.

The points where said device is to be applied are precisely established on the skin or on the nerve centre: they are the primary and secondary nerve endings of tendons, muscles, dermatomes and nerve endings, where you want to encourage the neuro-muscular and postural modulation, painful and inflammatory.

The very modest size of these emissions, comparable to an intensity of ULLLT (ultra low level laser therapy), to the fact that they are continuously applied (even for 24 hours a day) and that they are a combination of emissions centred precisely on the wavelength required, the effects and results of the invention can be obtained.

In fact, only thanks to the combination of the emissions that provide detensioning, reducing the pain, and the emissions that treat the neuro-muscular modulation, is it possible to get long-lasting and effective results.

First Example of an Application (FIGS.3-5)

By way of a non-limiting example, here is an application aimed at neuro-muscular modulation in a patient with tense chewing muscles.

These figures show how EMG electromyography (K7) is carried out on a patient with temporomandibular joint dysfunction, evaluated by a gnathologist dentist with and without devices of the invention.

All the measurement values of the left screen were collected before the application and the measured values of the right screen were collected a few minutes after the application of the devices of the invention.

Values above 2.4 uV are considered excessive muscular response/tension.

As can be seen from the legend, all the muscles treated RMM (Right Masseter), LMM (Left Masseter), LTA (Left Temporalis Anterior), RTA (Right Temporalis Anterior), LSM (Left SCM), RSM (Right SCM), had a reduction in resting tension measured using the electrical activation of the EMG muscle.

We can see a normalisation of muscular activation at rest, managing tensions on the patient.

In the left chart without devices, in fact, many muscles are overstimulated, i.e. they have values greater than 2.3 uV at rest with an average of 2.6 uV In the right chart we carry out the measurement after applying the devices with a symmetrical protocol, we can see an substantial normalisation of the patient with most of the muscles that already after just a few minutes drops below 2.4 uV with an average of 2.1 uV

Second Example of an Application (FIGS.6-8)

FIG.6shows a thermograph of inflammation created by a partial lesion of the tendon of the right rectus femoris of an Italian Serie A footballer.

We can see inFIG.8, (thermographic view inFIG.8and corresponding visible view inFIG.7) referring to the same limb of the same patient of the thermograph ofFIG.6, the reduction of the inflammation and the inflammation area24after the application of some devices of the invention suitably placed near the inflamed part.

Third Example of an Application (FIGS.9-11)

The application of the devices of the invention obtained an unexpected postural modulation. In fact, measuring, according to an assessment of the stabilometry (Cyber Sabot) compliant with the guidelines of the Ministry of Health regarding Posturology, the postural oscillations before (FIG.9) and after (FIG.10) the application of the devices of the invention to a patient suffering from rheumatic polymyalgia, we can see, as shown in the table inFIG.11, that the area has significantly reduced from 359 sq. mm to 98 sq. mm (results measured immediately after only a few minutes of application). Therefore the application of the devices of the invention favours a considerable energy saving in the management of the upright posture; this energy remains available to the body that can use it for other metabolic functions.

Fourth Example of an Application (FIGS.12-14)

The results attained by the devices of the invention applied to people suffering from multiple sclerosis are surprising.

These results are evaluated according to:The accelerometer testFIG.12on hip rotation, and lumbar flexion;The calculation of the international EDSS index (Expanded Disability Status Scale—Disability scale used for patients with Multiple Sclerosis)FIG.13;The SF36 self-assessment test (questionnaire on the health of the patient)FIG.14.

With reference toFIGS.12-13-14:T0 the condition of the patient without devices.T1 30 minutes from the application of the devices of the invention;T3 3 months from the application of the devices of the invention, with a continuous use of said devices;T4 1 year from the application of the devices of the invention, with a continuous use of said devices.

Comments on the results.

Accelerometer test.

The diagrams, for the right hip flexion, the left hip flexion, and for the lumbar flexion, show a significant improvement from T0 to T4 of the flexion, i.e. the rotation capacity of the right hip (p<0.05) and the left hip (p<0.01), and even more significant increases in lumbar flexion (flex-extension) (p<0.0009).

It should be noted that the improvements are evident at 3 months (T3) and remain constant in the 1-year control period (T4), demonstrating the constancy of the effects.

EDSS

This index showed a significant improvement with an average of 4.9 at time T0 to 4.7 at time T4. This data is highly significant (p<0.002), especially considering that in these patients the data should have gotten worse over time.

SF36

With the SF36 self-assessment, patients demonstrated significant improvements at 3 months, which remained constant at one year.

The improvements were noted for the physical as well as the emotional and social spheres, but greater for the emotional-social spheres. In particular, there were improvements in physical activity, the limitation of the physical role, pain, general health, vitality and physical health index (PHI), as regards the physical sphere.

Social activities, the limitation of the emotional role, mental health and the mental health index (MHI) improved, as regards the emotional-social sphere.